

TARO PHARMACEUTICALS INC.

BALANCE SHEETS

	March 31, 2023 (Unaudited) USD Dollars	March 31, 2022 (Unaudited) USD Dollars
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 116,608,187	\$ 203,847,761
Short-term bank deposits	64,500,000	-
Marketable securities	502,862,139	458,173,271
Trade accounts receivable	27,124,034	27,675,129
Other receivables and prepaid expenses:		
Prepaid expenses	2,731,111	3,534,501
Government authorities	5,208,198	9,736,622
Advances to suppliers	5,366,036	25,538
Derivative instruments	-	87,357
Intercompany balances and Loan	344,491,028	261,754,489
Other	8,183,594	6,772,862
TOTAL Other receivables and prepaid expenses	365,979,966	281,911,368
Inventories	84,762,552	76,329,069
TOTAL CURRENT ASSETS	1,161,836,878	1,047,936,599
LONG-TERM RECEIVABLES AND OTHER ASSETS	335,222,210	362,624,039
FIXED ASSETS:		
Cost	127,812,792	121,570,138
Less - accumulated depreciation	(71,055,919)	(64,421,193)
	56,756,874	57,148,945
GOODWILL	276,147	276,147
INTANGIBLE ASSETS AND DEFERRED COSTS, NET	68,108,506	79,675,201
INVESTMENT IN ASSOCIATED COMPANIES	372,600,002	367,117,780
INVESTMENT IN PARTNERSHIPS	2,000,000	-
DEFERRED INCOME TAXES	16,844,499	34,939,078
TOTAL ASSETS	\$ 2,013,645,115	\$ 1,949,717,789

TARO PHARMACEUTICALS INC.

BALANCE SHEETS

	March 31, 2022 (Unaudited) USD Dollars	March 31, 2021 (Unaudited) USD Dollars
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable:		
Trade payables	\$ 34,835,563	\$ 28,748,586
Other current liabilities:		
Returns reserve	8,186,473	7,897,462
Intercompany balances	5,196,275	4,260,069
Employees and payroll accruals	4,250,073	5,334,189
Deferred revenue	236,624	236,624
Medicaid and indirect rebates	6,054,342	6,664,628
Accrued expenses	15,459,510	10,452,918
Derivative instruments	-	180,601
Other	286,859	322,226
TOTAL Other current liabilities	<u>39,670,155</u>	<u>35,348,717</u>
TOTAL CURRENT LIABILITIES	<u>74,505,719</u>	<u>64,097,303</u>
LONG-TERM LIABILITIES:		
Other long-term liabilities	10,873,924	24,481,509
	<u>10,873,924</u>	<u>24,481,509</u>
SHAREHOLDERS' EQUITY	<u>1,928,265,472</u>	<u>1,861,138,977</u>
	<u>\$ 2,013,645,115</u>	<u>\$ 1,949,717,789</u>

Date of approval of the
financial statements

Thurga S. Mayuran
Director, Finance

STATEMENTS OF INCOME

	For the year Ended March 31, 2023 (Unaudited) USD Dollars	For the year Ended March 31, 2022 (Unaudited) USD Dollars	For the year Ended March 31, 2021 (Unaudited) USD Dollars
Sales	\$ 271,761,033	\$ 288,772,111	\$ 259,636,042
Cost of sales	176,877,851	169,630,345	177,495,026
Gross profit	94,883,181	119,141,765	82,141,016
Research and development	18,802,130	19,598,992	23,401,899
Selling and marketing expenses	11,613,777	10,750,192	10,389,199
General and administrative expenses	8,726,055	8,100,916	8,806,004
Operating income	55,741,220	80,691,666	39,543,915
Settlements and Loss Contingencies	-	18,623,673	62,254,128
Financing income (expenses), net	20,343,481	9,327,570	17,659,106
Other income (expense)	(1,810)	60,911	906,567
Income before taxes on income	76,082,891	71,456,473	(4,144,541)
Taxes on income	8,990,394	12,994,735	(12,713,298)
Net income for the period before subsidiaries and dividend	67,092,498	58,461,738	8,568,757
Dividend income, net	-	-	-
Subsidiaries	-	-	-
Net income for the period	\$ 67,092,498	\$ 58,461,738	\$ 8,568,757

TARO PHARMACEUTICALS INC.

Changes in Shareholders' Equity

USD Dollars

Unaudited

	Number of Shares (Unaudited)	Share Capital (Unaudited)	Additional Paid-in Capital (Unaudited)	Accumulated Other Comprehensive Income (Loss) (Unaudited)	Foreign Currency Translation Adj (Unaudited)	Retained Earnings (Unaudited)	Total Taro Shareholders' Equity (Unaudited)	Noncontrolling Interest (Unaudited)	Total Shareholders' Equity (Unaudited)
Balance at March 31, 2020 (USD)	12	372,607,244	263,098	(3,516,670)	(156,753,284)	1,587,378,422	1,799,978,810	-	1,799,978,810
Comprehensive income, net of tax	-	-	-	7,984,764	-	-	7,984,764	-	7,984,764
Net income	-	-	-	-	-	8,568,758	8,568,758.00	-	8,568,758
Balance at March 31, 2021 (USD)	12	372,607,244	263,098	4,468,094	(156,753,284)	1,595,947,180	1,816,532,332	-	1,816,532,332
Comprehensive income, net of tax	-	-	-	(13,855,093)	-	-	(13,855,093)	-	(13,855,093)
Net income	-	-	-	-	-	58,461,738	58,461,738.00	-	58,461,738
Balance at March 31, 2022 (USD)	12	372,607,244	263,098	(9,386,999)	(156,753,284)	1,654,408,918	1,861,138,977	-	1,861,138,977
Comprehensive income, net of tax	-	-	-	33,997	-	-	33,997	-	33,997
Net income (loss)	-	-	-	-	-	67,092,498	67,092,498	-	67,092,498
Balance at March 31, 2023 (USD)	12	372,607,244	263,098	(9,353,002)	(156,753,284)	1,721,501,416	1,928,265,472	-	1,928,265,472